Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0869, aprepitant · 7 trials · 5 indications
| Name | Type | Description |
|---|---|---|
| MK0869, aprepitant | DRUG | - |
| Comparator: ondansetron IV | DRUG | - |
| MK0869, aprepitant / Duration of Treatment: 3 days | DRUG | - |
| Comparator: placebo | DRUG | - |
| Comparator: paroxetine HCL | DRUG | - |
Inclusion Criteria: * Patient is at least 18 years of age. * Patient is scheduled to undergo open abdominal surgery requiring overnight hospital stay (24-hour hospital stay after end of surgery). * Patient is scheduled to receive general anesthesia. * Patient is scheduled to receive postoperative o...
Top 20 of 31 competitors
MK0869, also known as aprepitant, is a small molecule being studied for use in Major Depressive Disorder, Postoperative Nausea and Vomiting, and Nausea. It is developed by Merck & Company, Inc. and is currently in Phase 3 clinical development for these indications.
MK0869, also known as aprepitant, is a small molecule developed by Merck & Company, Inc. Its specific molecular target has not been disclosed in available clinical trial information. It is being investigated for psychiatric and nausea-related conditions.
MK0869, also known as aprepitant, is developed by Merck & Company, Inc., which trades under the ticker MRK. The drug is currently in Phase 3 clinical trials for Major Depressive Disorder, Postoperative Nausea and Vomiting, and Nausea.
MK0869, also known as aprepitant, is in Phase 3 clinical development. It is being studied for Major Depressive Disorder, Postoperative Nausea and Vomiting, and Nausea. All four completed trials were Phase 3, and the drug remains investigational for these uses.
MK0869, also known as aprepitant, has completed four Phase 3 trials. These include NCT00035009 for Major Depressive Disorder, NCT00090155 and NCT00090246 for Postoperative Nausea and Vomiting, and NCT00092196 for chemotherapy-induced Nausea and Vomiting in breast neoplasms.
Yes, MK0869 is the same as aprepitant. The drug is developed by Merck & Company, Inc. under the ticker MRK. It is being studied in Phase 3 trials for Major Depressive Disorder, Postoperative Nausea and Vomiting, and Nausea.